[go: up one dir, main page]

MX2012007234A - Nanocristales de monohidrato de calciprotiol. - Google Patents

Nanocristales de monohidrato de calciprotiol.

Info

Publication number
MX2012007234A
MX2012007234A MX2012007234A MX2012007234A MX2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A
Authority
MX
Mexico
Prior art keywords
calcipotriol monohydrate
monohydrate nanocrystals
nanocrystals
calcipotriol
prevention
Prior art date
Application number
MX2012007234A
Other languages
English (en)
Inventor
Karsten Petersson
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2012007234A publication Critical patent/MX2012007234A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen los nanocristales de monohidrato de calcipotriol preparados mediante el proceso de la presente, que pueden ser incorporados en una composición farmacéutica para el uso en la prevención o tratamiento de trastornos y condiciones dérmicas.
MX2012007234A 2009-12-22 2010-12-22 Nanocristales de monohidrato de calciprotiol. MX2012007234A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK2009000267 2009-12-22
US29309110P 2010-01-07 2010-01-07
PCT/DK2010/000183 WO2011076208A2 (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Publications (1)

Publication Number Publication Date
MX2012007234A true MX2012007234A (es) 2012-07-30

Family

ID=43618145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007234A MX2012007234A (es) 2009-12-22 2010-12-22 Nanocristales de monohidrato de calciprotiol.

Country Status (15)

Country Link
US (2) US20130039952A1 (es)
EP (1) EP2515874B1 (es)
JP (1) JP5816194B2 (es)
CN (1) CN102770125B (es)
AU (1) AU2010335655B2 (es)
BR (1) BR112012015449B1 (es)
CA (1) CA2785253A1 (es)
ES (1) ES2523119T3 (es)
IL (1) IL220516A (es)
MX (1) MX2012007234A (es)
NZ (1) NZ601000A (es)
PL (1) PL2515874T3 (es)
RU (1) RU2555339C2 (es)
WO (1) WO2011076208A2 (es)
ZA (1) ZA201204618B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918369C (en) * 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
KR20190042558A (ko) 2016-07-05 2019-04-24 크라토스 엘엘씨 부동태화된 예비리튬화된 마이크론 및 서브마이크론 iva족 입자 및 이의 제조방법
US11637280B2 (en) 2017-03-31 2023-04-25 Kratos LLC Precharged negative electrode material for secondary battery
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
CN109157661B (zh) * 2018-09-10 2021-09-24 南京工业大学 一种配体辅助下用氧化物silica包覆疏水性分子晶体的方法
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза
JP7751298B2 (ja) * 2021-07-14 2025-10-08 株式会社ツツミプランニング 浸透深さの調整方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315787D0 (en) * 1983-06-08 1983-07-13 Briggs J H Coolant spray
US4758432A (en) * 1984-10-15 1988-07-19 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9300763D0 (en) * 1993-01-15 1993-03-03 Leo Pharm Prod Ltd Chemical compound
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6403654B1 (en) * 2000-04-13 2002-06-11 Mariana De Oliveira Compositions for and method of treatment for psoriasis
PL212660B1 (pl) * 2000-10-27 2012-11-30 Leo Pharma As Zasadniczo niewodna zelowa kompozycja farmaceutyczna do podawania na skóre oraz jej zastosowanie
EP1339390A2 (en) * 2000-12-06 2003-09-03 Pharmacia Corporation Laboratory scale milling process
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
CA2530302C (en) 2003-07-24 2013-12-03 Leo Pharma A/S Novel aminobenzophenone compounds
EP1742612A2 (en) * 2004-05-06 2007-01-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
ES2341473T3 (es) 2004-12-13 2010-06-21 Leo Pharma A/S Compuestos de aminobenzofenona sustituida con triazol.
ES2447301T3 (es) * 2005-06-01 2014-03-11 Glaxosmithkline Intellectual Property Development Limited Formulación vitamínica
WO2007050543A2 (en) * 2005-10-24 2007-05-03 Collegium Pharmaceutical, Inc. Topical pharmaceutical foam composition
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008058755A1 (en) * 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
HRP20110464T1 (hr) 2006-12-22 2011-07-31 Leo Pharma A/S Supstituirani acetofenoni korisni kao inhibitori pde4
SI2114951T1 (sl) 2007-02-28 2014-08-29 Leo Pharma A/S Novi zaviralci fosfodiesteraze
CN101677979A (zh) 2007-04-19 2010-03-24 利奥制药有限公司 Src家族激酶抑制剂
EP2146780A1 (en) 2007-05-11 2010-01-27 Sonneborn Inc. Petrolatums having silicone-like properties
WO2010069322A1 (en) 2008-12-19 2010-06-24 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Also Published As

Publication number Publication date
JP5816194B2 (ja) 2015-11-18
AU2010335655A1 (en) 2012-07-19
NZ601000A (en) 2014-07-25
JP2013515019A (ja) 2013-05-02
CA2785253A1 (en) 2011-06-30
BR112012015449B1 (pt) 2021-09-28
CN102770125B (zh) 2015-02-11
ES2523119T3 (es) 2014-11-21
HK1177694A1 (en) 2013-08-30
RU2555339C2 (ru) 2015-07-10
US20140322331A1 (en) 2014-10-30
EP2515874A2 (en) 2012-10-31
CN102770125A (zh) 2012-11-07
US20130039952A1 (en) 2013-02-14
IL220516A (en) 2015-06-30
ZA201204618B (en) 2013-09-25
AU2010335655B2 (en) 2015-03-05
EP2515874B1 (en) 2014-08-20
WO2011076208A2 (en) 2011-06-30
PL2515874T3 (pl) 2015-01-30
RU2012130412A (ru) 2014-01-27
WO2011076208A3 (en) 2012-03-01
BR112012015449A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
IL244293A0 (en) Pharmaceutical preparation and method of treatment for emergency contraception
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
IN2012DN00971A (es)
MX2009010407A (es) Derivados fluorados de deferiprona.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
PT2429515T (pt) Novos medicamentos para uso tópico à base de ácido hialurónico sulfatado como agente de ativação ou inibição da atividade citoquínica
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
PH12012501389A1 (en) Hedgehog inhibitors
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
PL2470213T3 (pl) Kompozycje do leczenia chorób lub zaburzeń neurodegeneracyjnych, sposób i zastosowanie obejmujące elektromagnetycznie napromienione drożdże
PL2375912T3 (pl) Kompozycje i sposoby leczenia uczucia dyskomfortu gardła
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
WO2011075605A3 (en) Hyperglycosylated interferon variants and methods of use
WO2010149658A3 (en) Pharmaceutical composition comprising gamma - butyrobetaine and meldonium
UA56130U (ru) Способ лечения и профилактики телязиоза
HU0800083D0 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases

Legal Events

Date Code Title Description
FG Grant or registration